• IX Biopharma announced share allotments involving directors, the CEO and a substantial shareholder on 13 May 2026.
• Directors Teo Woon Keng John and Albert Ho Shing Tung were each allotted 99,051 ordinary shares in lieu of directors’ fees amounting to S$41,750 each.
• Executive Director and CEO Eddy Lee Yip Hang received 1,012,332 ordinary shares arising from the vesting of share awards.
• Substantial shareholder Anson Properties Pte. Ltd. was allotted 1,045,164 ordinary shares, increasing its stake in the Company from 5.96% to 6.03%.

IX Biopharma Ltd. announced changes in shareholdings involving directors, the CEO and a substantial shareholder following the allotment and issuance of new ordinary shares on 13 May 2026.

As approved by shareholders at the Extraordinary General Meeting held on 8 May 2026, Directors Teo Woon Keng John and Albert Ho Shing Tung were each allotted 99,051 ordinary shares, valued at S$41,750 each, in lieu of cash payment for directors’ fees for the period from 1 October 2025 to 31 March 2026. 

Separately, Executive Director and CEO Eddy Lee Yip Hang received 1,012,332 ordinary shares arising from the vesting of share awards, increasing his total interest in the Company from 236.79 million shares to 237.81 million shares. Following the vesting, his total interest in the Company stood at approximately 22.5%. 

In addition, substantial shareholder Anson Properties Pte. Ltd. was allotted 1,045,164 ordinary shares valued at S$440,537, increasing its direct shareholding in IX Biopharma from 62.75 million shares (5.96%) to 63.79 million shares (6.03%).